We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+3.81%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$1.06B
AUM Growth
-$97.3M
Cap. Flow
-$112M
Cap. Flow %
-10.55%
Top 10 Hldgs %
99.95%
Holding
11
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$15.7M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$84.8M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$42.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$369M 34.92%
14,040,000
– –
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$696M
$206M 19.49%
16,390,000
– –
BIIB icon
3
Biogen
BIIB
$30B
$135M 12.8%
643,000
– –
INVA icon
4
Innoviva
INVA
$1.55B
$128M 12.1%
6,614,000
– –
GILD icon
5
Gilead Sciences
GILD
$162B
$92.9M 8.78%
1,562,900
-1,326,400
-46% -$84.8M
AMRN
6
Amarin Corp
AMRN
$299M
$79M 7.46%
1,200,000
+237,500
+25% +$15.7M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.28B
$22.6M 2.14%
1,390,790
-2,648,810
-66% -$42.5M
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$17.2M 1.62%
171,972
– –
VOR icon
9
Vor Biopharma
VOR
$1.15B
$4.27M 0.4%
35,351
– –
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$2.53M 0.24%
500,356
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$552K 0.05%
185,185
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Sarissa Capital Management held 11 positions worth $1.06B, down 8.4% from $1.16B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management withdrew a net $112M in Q1 2022, reducing 2 holdings. Its largest reduction was Gilead Sciences, cutting an estimated $84.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Sarissa Capital Management added an estimated $15.7M to Amarin Corp.

  • Sarissa Capital Management added most to Amarin Corp in Q1 2022, an estimated $15.7M increase.
  • Sarissa Capital Management's biggest Q1 2022 reduction was Gilead Sciences, cutting an estimated $84.8M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $1.06B portfolio in Q1 2022.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q1 2022.
  • Sarissa Capital Management's portfolio value fell 8.4% quarter-over-quarter to $1.06B.

Based on Sarissa Capital Management's 13F filing for Q1 2022, filed 16 May 2022.